Chlamydia pneumoniae infection
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
adults
macrolides or fluoroquinolones or tetracyclines
Data on microbiological efficacy based on culture are limited; the results of three published treatment studies in adults that used cultures demonstrated 70% to 80% eradication of Chlamydia pneumoniae from the respiratory tract in adults with community-acquired pneumonia after treatment with azithromycin, levofloxacin, or moxifloxacin.[13]Hammerschlag MR, Roblin PM. Microbiologic efficacy of levofloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother. 2000 May;44(5):1409. http://aac.asm.org/cgi/content/full/44/5/1409 http://www.ncbi.nlm.nih.gov/pubmed/10819727?tool=bestpractice.com [14]Hammerschlag MR, Roblin PM. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents. 2000 Jul;15(2):149-52. http://www.ncbi.nlm.nih.gov/pubmed/10854812?tool=bestpractice.com [21]Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithro-mycin and susceptibility to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community acquired pneumonia. Antimicrob Agents Chemother. 1998 Jan;42(1):194-6. http://aac.asm.org/cgi/content/full/42/1/194 http://www.ncbi.nlm.nih.gov/pubmed/9449287?tool=bestpractice.com These three drugs appear to be equivalent and can be considered first-line.
Tetracyclines, specifically doxycycline, are also used first-line.
Tetracyclines and fluoroquinolones cannot be used in pregnant women. Treatment in this group should be with a macrolide (azithromycin, clarithromycin, or erythromycin).
Fluoroquinolones are associated with serious, disabling, and potentially irreversible adverse effects including tendonitis, tendon rupture, arthralgia, neuropathies, and other musculoskeletal or nervous system effects.[15]European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. Mar 2019 [internet publication]. https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products [16]Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Mar 2018 [internet publication]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics The Food and Drug Administration (FDA) has also issued warnings about the increased risk of aortic dissection, significant hypoglycaemia, and mental health adverse effects in patients taking fluoroquinolones.[17]Food and Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. Dec 2018 [internet publication]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics [18]Food and Drug Administration. FDA Drug Safety Communication: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Jul 2018 [internet publication] https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side
Primary options
azithromycin: 500 mg orally once daily on day one, followed by 250 mg once daily for 4 days
OR
levofloxacin: 500 mg orally/intravenously once daily for 7-14 days
OR
moxifloxacin: 400 mg orally/intravenously once daily for 10 days
OR
doxycycline: 100 mg orally twice daily for 14-21 days
OR
tetracycline: 250 mg orally every 6 hours for 14-21 days
OR
clarithromycin: 250 mg orally twice daily for 10 days
OR
erythromycin base: 500 mg orally every 6 hours for 14-21 days
children
macrolides
Treatment is with either a 10-day course of erythromycin or clarithromycin, or a 5-day course of azithromycin suspension.[19]Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in community acquired pneumonia in children: comparative safety and efficacy of clarithromycin and erythromycin suspensions. Pediatr Infect Dis J. 1995 Jun;14(6):471-7. http://www.ncbi.nlm.nih.gov/pubmed/7667050?tool=bestpractice.com [20]Harris J-A, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community acquired pneumonia in children. Pediatr Infect Dis J. 1998 Oct;17(10):865-71. http://www.ncbi.nlm.nih.gov/pubmed/9802626?tool=bestpractice.com
All these regimens have demonstrated 80% efficacy in eradication of Chlamydia pneumoniae from the respiratory tract of children.
Primary options
erythromycin base: 50 mg/kg/day orally given in divided doses every 6 hours for 10-14 days
OR
clarithromycin: 15 mg/kg/day orally given in divided doses every 12 hours for 10 days
OR
azithromycin: 10 mg/kg/day orally on day one, followed by 5 mg/kg/day for 4 days
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer